洛铂与顺铂新辅助序贯同步放化疗治疗ⅡB～ⅢB期宫颈癌的疗效分析#br##br#

目的探讨洛铂与顺铂新辅助序贯同步放化疗治疗ⅡB～ⅢB期宫颈的疗效。方法选择2019年1月至2020年12月池州市人民医院收治的84例宫颈癌患者为研究对象,以随机数字表法分为观察组（n=42）与对照组（n=42）。对照组采用顺铂新辅助序贯同步放化疗,观察组采用洛铂新辅助序贯同步放化疗,两组均治疗6个周期后,比较两组临床控制率、治疗前后血清鳞状上皮细胞癌抗原（SCC）、癌胚抗原（CEA）、CD4+/CD8+及自然杀伤（NK）细胞水平,比较两组治疗期间不良反应发生率,随访1年,比较两组生存预后情况。结果治疗后,观察组临床控制率（9524%）与对照组（9048%）差异无统计学意义（P>005）;两组血清CEA、SCC水平均较治疗前降低,差异有统计学意义（P<005）,两组血清CEA、SCC水平治疗前后差值差异无统计学意义（P>005）;观察组CD4+/CD8+及NK细胞水平高于对照组,差异有统计学意义（P<005）,观察组CD4+/CD8+及NK细胞水平治疗前后差值均低于对照组,差异有统计学意义（P<005）;两组血小板减少、中性粒细胞减少、恶心、呕吐等不良反应发生率比较差异无统计学意义（P>005）;两组随访1年的无进展生存情况差异无统计学意义（P>005）。结论洛铂与顺铂新辅助序贯同步放化疗治疗ⅡB～ⅢB期宫颈癌的临床疗效相当,安全可靠,两种方法的无进展生存期差异无统计学意义,但洛铂新辅助序贯同步放化疗可减少对免疫反应的干扰。

Efficacy analysis of neoadjuvant sequential concurrent chemoradiotherapy with lobaplatin and cisplatin in the treatment of stage IIB-IIIB cervix

Objective To investigate the efficacy of lobaplatin and cisplatin neoadjuvant sequential concurrent chemoradiotherapy in the treatment of stage IIB-IIIB cervix.Methods A total of 84 patients with cervical cancer admitted to the hospital from January 2019 to December 2020 were selected as the research objects, and they were divided into anobservation group group (n=42) and a control group (n=42) by a random number table method. The control group was treated with cisplatin neoadjuvant sequential concurrent chemoradiotherapy, and the observation groupwas treated with lobaplatin neoadjuvant sequential concurrent concurrent chemoradiotherapy. After 6 cycles of treatment in both groups, the clinical control rates of the two groups were compared. The clinical control rate, serum squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA) levels, CD4+/CD8+ and NK cell levels before and after treatment between the two groups, and adverse reactions during treatment between the two groups were compared.ResultsAfter treatment, the clinical control rate of the observation group (95.24%) was higher than that of the control group (90.48%), but the difference was not statistically significant (P>0.05). The serum levels of CEA and SCC in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). There were no significant difference in serum CEA and SCC levels between the two groups before and after treatment (P>0.05). The levels of NK cells and CD4+/CD8+ in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). The differences of CD4+/CD8+ and NK cell levels in the observation group before and after treatment were lower than those in the control group, and the difference was statistically significant (P<0.05). There were no significant difference in the incidence of adverse reactions such as thrombocytopenia, neutropenia, nausea and vomiting between the two groups (P>0.05). There were no significant difference in the one-year follow-up progression-free survival curve between the two groups (P>0.05). ConclusionLoboplatin and cisplatin neoadjuvant sequential concurrent chemoradiotherapy in the treatment of stage IIB-IIIB cervical cancer, the clinical efficacy is equivalent, safe and reliable, and has no effect on progression-free survival, but lobaplatin neoadjuvant sequential concurrent concurrent chemoradiotherapy can reduce the immune response.